In a late-stage trial, personalized mRNA vaccines for melano...Web Page - kottke.org
kottke.org

In a late-stage trial, personalized mRNA vaccines for melano...

In a late-stage trial, personalized mRNA vaccines for melanoma “reduced the risk of death or recurrence by 42 percent compared to standard treatment”.

This site doesn’t allow embedding inside another page — open it in a new tab. Your Weird rating still works from the top bar.

Open source